Male Breast Cancer Clinical Trial
Official title:
Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens
The aim of this study is to define silent breast cancer prevalence in both sexes and will be held by biopsies performed in imaging suspicious areas of the breast (ecography and mammography) in cadavers without known breast cancer.
Cadavers of both sexes are going to be submitted to bilateral mastectomy. The specimens are
going to be examined by palpation, ecography and mammography and all areas with (Breast
Imaging Reporting and Data System) BI-RADS classification >= 3 are going to be biopsied.
Biopsy specimens are going to be processed by the pathology department and cancers are going
to be identified and classified by their molecular type.
The investigators intend to know which is the disease reservoir in various ages.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01705340 -
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
| Terminated |
NCT01222377 -
Endoscopic Breast Surgery in Treating Patients With Breast Cancer
|
N/A | |
| Completed |
NCT00244881 -
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
|
Phase 2 | |
| Completed |
NCT00425672 -
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
|
Phase 1/Phase 2 | |
| Completed |
NCT00096434 -
Sorafenib in Treating Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
| Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT00791037 -
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00559507 -
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
| Completed |
NCT00119262 -
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT00098605 -
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
|
Phase 2 | |
| Terminated |
NCT00095888 -
3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT00068588 -
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT00071942 -
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT05501704 -
ETHAN - ET for Male BC
|
Phase 2 | |
| Completed |
NCT01869764 -
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
|
Phase 2 | |
| Completed |
NCT02046421 -
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1 | |
| Completed |
NCT01720602 -
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
|
N/A | |
| Completed |
NCT01493310 -
Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Terminated |
NCT01931709 -
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
|
N/A |